Belkin Announces All-New Accessories for Apple Vision Pro at Web Summit 2024
Belkin, a leading consumer electronics brand for 40 years, today announced two new additions to its Apple Vision Pro accessories ecosystem — providing users with new ways to experience the revolutionary device. Belkin’s Apple Vision Pro accessories include the Battery Holder released earlier this year, and today the collection adds Travel Bag and Head Strap. The portfolio is now available to order at belkin.com, apple.com and select Apple Store locations worldwide.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241111678245/en/
Belkin announces Head Strap and Travel Bag for Apple Vision Pro at Web Summit 2024 (Photo: Business Wire)
“Since 1983, Belkin has been at the forefront of innovation, shaping the accessories ecosystem with every leap in hero devices. From pioneering the original cable that connected the Apple IIc to a parallel printer, we've been driving progress—leading the way and pushing boundaries wherever technology evolves," said Steve Malony, CEO, Belkin. “Fast forward to today, where Apple Vision Pro is transforming the way people interact with content. We are continuing to revolutionize the accessories ecosystem to multiply and amplify the ways that consumers and businesses use this powerful spatial computer.”
Head Strap for Apple Vision Pro
The Head Strap enhances comfort and stability for Apple Vision Pro users with its ergonomic and adjustable design. It is thoughtfully engineered with reinforced seams, a secure locking mechanism, and additional stabilization points to keep Vision Pro firmly in place on the user with weight evenly distributed. The easily adjustable strap ensures a precise fit for a wide range of head sizes.
Travel Bag for Apple Vision Pro
The Travel Bag is designed to protect Apple Vision Pro when taking it on-the-go. It is compact and lightweight and can be carried using the handle, or with the adjustable straps in either shoulder or cross-body style. The multi-compartment design keeps Vision Pro and accessories, such as the battery, power adapter and head bands — all organized and easily accessible. It is engineered with an internal flap and cushioned base for additional protection. The deep front zipper makes access easy, and additional pockets allow for extra storage for personal items. The Travel Bag is made with lightweight, high-performance fabric for durability, and comes in a timeless space gray color option.
These two products join Belkin’s Battery Holder for Apple Vision Pro. Designed to keep the battery’s position secure, the Battery Holder allows for a convenient and versatile hands-free experience.
Pricing and Availability
The Head Strap is available to order now for $49.95 USD on belkin.com, apple.com and select Apple Store locations in the US, China, Hong Kong, Japan, Singapore, Australia, Canada, France, Germany, and the UK.
The Travel Bag is available to order now for $99.95 USD on belkin.com, apple.com and select Apple Store locations in the US, China, Hong Kong, Japan, Singapore, Australia, Canada, France, Germany, and the UK.
The Battery Holder is available to order now for $49.95 USD on belkin.com, apple.com and select Apple Store locations in the US, China, Hong Kong, Japan, Singapore, Australia, Canada, France, Germany, and the UK.
Media kit available for download HERE.
About Belkin
Belkin is a California-based accessories leader delivering award-winning power, protection, productivity, connectivity, and audio products over the last 40 years. Designed and engineered in Southern California and sold in more than 100 countries around the world, Belkin has maintained its steadfast focus on research and development, community, education, sustainability and most importantly, the people it serves. From our humble beginnings in a Southern California garage in 1983, Belkin has become a diverse, global technology company. We remain forever inspired by the planet we live on, and the connection between people and technology.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241111678245/en/
Contacts
Media Contact
Jen Wei
VP Global Communications and Corporate Development
comms@belkin.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Nemluvio ® (Nemolizumab) for Patients with Moderate-to-Severe Atopic Dermatitis13.12.2024 23:09:00 CET | Press Release
Galderma (SWX:GALD) today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Nemluvio® (nemolizumab) for the treatment of patients 12 years and older with moderate-to-severe atopic dermatitis, in combination with topical corticosteroids (TCS) and/or calcineurin inhibitors (TCI) when the disease is not adequately controlled with topical prescription therapies. This follows the recent U.S. FDA approval of Nemluvio for subcutaneous injection for the treatment of adults with prurigo nodularis in August 2024.12 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241213562840/en/ Atopic dermatitis affects more than 230 million people worldwide, impacting approximately 7% of people in the U.S.2-4 Often reported as one of patients’ most problematic symptoms, 87% of people with atopic dermatitis say they are seeking freedom from itch, with speed of itch relief therefore also prioritized by both patient
Experian’s 2024 Global Identity & Fraud Report Spotlights Huge Growth in Highly Personalized GenAI-Driven Fraud Attacks13.12.2024 15:00:00 CET | Press Release
Today, Experian announced its 2024 Global Identity & Fraud Report that provides a comprehensive view of the consumer and business response to the latest fraud patterns and fraud‑mitigation strategies in the worldwide financial services sector. The report offers combined insights from more than 1,000 businesses and fraud leaders globally, as well as 4,000 consumers, focusing on fraud management and the digital experience. Among its key insights, the report casts a bright spotlight on three factors driving the fast-evolving fraud landscape: the huge growth in Generative Artificial Intelligence (GenAI) technologies, changing government regulations, and the push among businesses to provide consumers with secure and convenient digital experiences. In response to these factors, the report’s findings revealed that businesses intend to increase fraud budgets driven by investments in AI and machine learning technologies. “Unlike other issues facing financial services companies, fraud operates b
Capcom Announces Onimusha Way of the Sword , Marking the First New Title in the Series in Over 20 Years! Work on an Okami Sequel Project Begins!13.12.2024 14:00:00 CET | Press Release
Capcom Co., Ltd. (TOKYO:9697) today announced that Onimusha Way of the Sword, the first new title in the Onimusha series in over 20 years, is scheduled to be released, while work on an Okami sequel project has also started. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241213232085/en/ Onimusha Way of the Sword (Graphic: Business Wire) The Onimusha series consists of swordplay action games where players assume the role of warriors with the superhuman powers of the Oni and fight against monsters bent on world domination. Onimusha Way of the Sword, scheduled to be released globally in 2026, is a Japanese-inspired dark fantasy game set at the beginning of the Edo period in Kyoto, which has been eerily transformed by clouds of Malice. In the game, the samurai protagonist is equipped with the Oni Gauntlet and engages in epic sword battles with the grotesque and otherworldly creatures known as Genma. Capcom hopes that players loo
BrightPath Bio and Cellistic Announces Process Development and Manufacturing Collaboration for Phase 1 Clinical Trial of iPSC-derived BCMA CAR-iNKT cell13.12.2024 13:51:00 CET | Press Release
BrightPath Bio (Tokyo Stock Exchange Growth 4594, “BrightPath”), a pioneer in iPS cell-derived Natural Killer T (“NKT”) cell therapy, and Cellistic, a leader in advanced iPS cell therapy manufacturing, today announced a process development and manufacturing agreement to advance BrightPath’s novel allogeneic CAR-T cell therapy platform, utilizing iPSC-derived NKT cells for clinical trials. The strategic collaboration includes the use of Cellistic's innovative 3D bioreactor-based manufacturing platform, Echo, to enable GMP-compliant, clinical-scale manufacturing of iPSC-derived BCMA-targeting CAR-NKT cells for Phase 1 multiple myeloma trial; establishing BrightPath as a first mover in this emerging field. “The use of NKT cells as effectors in allogeneic CAR-T therapy represents a promising strategy, offering not only direct cytotoxicity but also indirect anti-tumor activity through the priming of host CD8+ T cells—a mechanism expected to evade host immune rejection and to enhance the dur
CHMP Recommends Approval of Galderma’s Nemolizumab for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis in the European Union13.12.2024 07:00:00 CET | Press Release
Galderma today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting the marketing authorization of nemolizumab for the treatment of both atopic dermatitis and prurigo nodularis in the European Union (EU). The CHMP has recommended nemolizumab’s approval for subcutaneous use for the treatment of moderate-to-severe atopic dermatitis in patients aged 12 years and older who are candidates for systemic therapy, and for subcutaneous use for the treatment of adults with moderate-to-severe prurigo nodularis who are candidates for systemic therapy. This follows its approval for the treatment of adults with prurigo nodularis by the United States (U.S.) Food and Drug Administration (FDA) in August 2024.14 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241212936857/en/ Atopic dermatitis is a common, chronic, and flaring infl
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom